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chemotherapy by stabilizing endothelial HIF-2α
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One drawback of chemotherapy is poor drug delivery to tumor cells, due in part to hyper-
permeability of the tumor vasculature. Extracellular superoxide dismutase (SOD3) is an
antioxidant enzyme usually repressed in the tumor milieu. Here we show that specific SOD3
re-expression in tumor-associated endothelial cells (ECs) increases doxorubicin (Doxo)
delivery into and chemotherapeutic effect on tumors. Enhanced SOD3 activity fostered
perivascular nitric oxide accumulation and reduced vessel leakage by inducing vascular
endothelial cadherin (VEC) transcription. SOD3 reduced HIF prolyl hydroxylase domain
protein activity, which increased hypoxia-inducible factor-2α (HIF-2α) stability and enhanced
its binding to a specific VEC promoter region. EC-specific HIF-2α ablation prevented both the
SOD3-mediated increase in VEC transcription and the enhanced Doxo effect. SOD3, VEC,
and HIF-2α levels correlated positively in primary colorectal cancers, which suggests a similar
interconnection of these proteins in human malignancy.
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The endothelium forms the inner blood vessel barrier thatregulates fluid, molecule and cell exchange between bloodand interstitial tissues. From a molecular viewpoint, this
endothelial barrier relies on several cell–cell adhesion systems in
endothelial cells (ECs), including adherens junctions (AJ), and
tight junctions (TJ), whose control is essential for vascular
homeostasis1. In cancer, endothelial junction composition and
function undergo extreme alterations that lead to massive edema
and increased interstitial pressure; this reduces tumor perfusion
and limits delivery of therapeutic agents2,3. Impaired blood flow
in leaky vessels also aggravates hypoxia, which lends tumor cells
greater resistance to anticancer compounds. Preservation of the
endothelial barrier is thus of great clinical interest in oncology.
Vascular endothelial cadherin (VEC; cadherin 5, CD144) is
responsible for endothelial AJ assembly and barrier archi-
tecture1,4. VEC mediates homophilic adhesion through cadherin
repeats in its extracellular domain. The VEC intracellular region
interacts with cytoplasmic proteins such as β-catenin and p120-
catenin; these anchor VEC to the actin cytoskeleton and control
VEC-elicited signals including modulation of the EC response to
angiogenic factors, quiescence and polarity signals, and EC
interaction with mural cells1. VEC also regulates transcription of
the TJ protein claudin-55, which pinpoints VEC as a cornerstone
in EC intercellular junction organization. In embryos and adults,
slight changes in VEC function, localization, or expression
severely destabilizes the vasculature6. Given its role in EC junc-
tion strength and plasticity, changes in VEC levels or trafficking
are recurrently altered manifestations of the twisted, leaky blood
vessel network in tumors1,3.
Low oxygen tension, or hypoxia, is a hallmark of the tumor
microenvironment and a major factor leading to EC dysfunction7.
The adaptive cellular response to hypoxia is mediated by the basic
helix-loop-helix/PERN-ARNT-SIM hypoxia-inducible transcrip-
tion factors (HIF-1 and −2), heterodimers composed of HIF-α
and -β subunits. HIF-β subunits are constitutively expressed and
stable, whereas HIF-α subunits are regulated precisely by the HIF
prolyl hydroxylase domain proteins (PHD1–3). In normoxic
conditions, PHD enzymes hydroxylate two proline residues of
HIF-α, which triggers binding of the Von Hippel-Lindau (VHL)
E3 ubiquitin ligase to this subunit, and its subsequent ubiquiti-
nation and degradation8,9. In hypoxia, PHD become inactive,
which stabilizes HIF-α subunits and triggers functional HIF
heterodimers. Increased HIF levels in cancer cells induce over-
production of angiogenic factors such as vascular endothelial
growth factor (VEGF), which in turn promotes angiogenesis and
vessel leakiness10. Systemic postnatal ablation of PHD2 induces
hyperactive angiogenesis due to HIF-1 (but not HIF-2) stabili-
zation in internal organs11. EC-specific partial reduction of PHD2
levels does not increase vascular density in tumors however, but
tightens EC adhesion by increasing VEC transcription, which
improves vascular function and chemotherapeutic drug deliv-
ery12,13. These effects are associated with HIF-2α (but not HIF-
1α) stabilization in PHD2+/− haploinsufficient EC12; HIF-2α (also
termed EPAS-1) but not HIF-1α induces VEC transcription14.
Preclinical and clinical evidence shows that HIF-2α inhibitors
reduce neoangiogenesis and growth of human renal clear cell
carcinomas, a neoplasia characterized by VHL tumor-suppressor
inactivation15,16. HIF-2α effects on the tumor milieu thus appear
to be cell type specific and dose dependent, suggesting that cancer
therapy can be enhanced by selective, precise HIF-2α stabilization
in endothelial but not in cancer cells.
Nitric oxide (NO) is a regulator of PHD activity and hence of
HIF-α levels. In normoxia, NO stabilizes HIF-1α in epithelial cells
by inhibiting PHD17. Perivascular NO accumulation also reduces
vascular permeability, increases tumor oxygenation, and
improves response to radiotherapy18. NO levels must nonetheless
be regulated precisely, since both inhibition and excess NO
synthesis can induce AJ disassembly and vascular hyperperme-
ability19,20. These paradigmatic NO activities could be a result of
its reaction with other environmental co-signals such as the
superoxide free radical (·O2−). ·O2− concentrations not only
determine NO steady-state levels but also the formation of highly
reactive nitrogen species such as peroxynitrite (·ONOO−); indeed,
HIF-α stability in human cerebral vascular smooth muscle cells
(VSMCs) depends on NO and ·O2− levels21.
SOD3 (or extracellular superoxide dismutase) is a secreted
enzyme that regulates the tissue redox balance by catalyzing ·O2−
dismutation to H2O222. In contrast to intracellular SOD, SOD3 is
expressed strongly in specific tissues and cells, including EC23.
SOD3 has a tissue-protective role in the perivascular space by
preventing oxidative damage of proteins and lipids and by
preserving NO availability24. By controlling NO/·O2− reactions,
SOD3 enhances NO-dependent vasorelaxation25, which high-
lights its importance in vascular function. SOD3 effects in cancer
biology, particularly on tumor vasculature, are poorly under-
stood26, although low SOD3 levels are associated with increased
cancer incidence and poor prognosis27–32. Here we used
pharmacological and genetic approaches to determine that
restoration of SOD3 levels in tumors regulates tumor vasculature
and increases the tumor response to chemotherapy.
Results
SOD3 upregulation potentiates doxorubicin effect on tumors.
We first analyzed whether SOD3 affects the tumor response to
chemotherapy. SOD3 is usually downregulated in tumors com-
pared to normal tissue30. Lovastatin (Lov) upregulates SOD3 in
spontaneous mammary tumors in mice33, which make Lov a
useful strategy for inducing SOD3 in the tumor environment.
We generated subcutaneous tumors by injecting Lewis lung
adenocarcinoma (LLC) cells in syngeneic wild-type (WT) and
SOD3-deficient mice (SOD3−/−). SOD3−/− mice do not display
any overt phenotype in basal conditions22, and there were no
major differences in EC marker expression compared to WT mice
(Supplementary Fig. 1). Tumor-bearing mice were treated daily
with a Lov dose equivalent to that in humans treated with 40 mg/
day34, or with vehicle (Vhcl) as control, starting at day 7 post-
implant. A suboptimal doxorubicin (Doxo) dose was co-
administered to mice. Although Lov alone did not affect tumor
growth kinetics, it increased the Doxo antitumor effect in WT
(Fig. 1a) but not in SOD3−/− mice (Fig. 1b). This enhancement
correlated with a two-fold increase in Doxo levels in Lov-
compared to Vhcl-treated WT mouse tumors (Fig. 1c); Lov
treatment had no effect on Doxo levels in tumors in SOD3−/−
mice.
Lov induced SOD3 in LLC tumors in WT but not in SOD3−/−
mice (Supplementary Fig. 2a, b); this induction was also apparent
in tumor sections (Fig. 1d). Although SOD3 is a soluble protein
that can diffuse in the extracellular milieu, we observed a
tendency to perivascular SOD3 accumulation in Lov-treated
tumors grown in WT hosts. Staining of 3-nitrotyrosine (3-NT; a
surrogate oxidative stress marker) in LLC tumors was reduced by
Lov treatment in WT but not in SOD3−/− mice (Fig. 1e); these
data linked the SOD3 increase to higher antioxidant activity in
tumors from Lov-treated WT mice. To define the Lov-targeted
cell types, SOD3 mRNA was quantified in LLC cells, leukocytes
(CD45+), and ECs (CD31+) isolated from tumors grown in Vhcl-
and Lov-treated WT and SOD3−/− mice. Lov minimally changed
SOD3 mRNA in LLC cells in both mouse types (Fig. 1f) but
induced a significant increase in leukocytes and ECs isolated from
tumors in WT mice (Fig. 1f). This SOD3 upregulation was not
observed in leukocytes or ECs from tumor-free spleen and lung
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Fig. 1 SOD3 upregulation enhances Doxo chemotherapeutic effects. a, b LLC tumor growth kinetics in Vhcl-, Lov-, Doxo+Vhcl-, or Doxo+Lov-treated WT
(a) and SOD3−/− mice (b). Arrows indicate treatment schedule (n= 10 mice/group). c Tumors from WT or SOD3−/− mice treated as above were
dissected on day 16 and Doxo was quantified in tumor extracts. d Vhcl- and Lov-treated tumors from WT or SOD3−/− mice were dissected on day 18 (<1
cm3), and SOD3 and CD31 were detected in cryosections by immunohistochemistry (IHC); the two-color merge is shown (n= 10 fields/group; 4 mice/
group). e 3-NT detection in paraffin sections of LLC tumors as in d (n= 15 fields/group; 4 mice/group). f LLC-GFP cells were implanted in WT or SOD3−/−
mice, Lov-treated as in a, and tumors were dissected on day 21. LLC cells, ECs, and leukocytes were isolated by cell sorting and SOD3 mRNA was
determined by qPCR. Data shown as mean± SEM of triplicates (n= 5 mice/group). g Detection of SOD3 expression (red) and CD31 (green) in sections of
Ad-C- or Ad-mSOD3-injected LLC tumors (dissected on day 18); nuclei are DAPI-stained (blue). Arrows in the SOD3 panel indicate the position of CD31+
cells. Bottom panel shows SOD3 fluorescence intensity quantified by ImageJ (15 images/group; 4 mice/group). h Growth kinetics of Ad-C- or Ad-mSOD3-
injected LLC tumors. Arrows indicate treatment schedule (n= 9 mice/group). i Doxo quantification in extracts of tumors dissected on day 16 from mice
treated as in h. *p< 0.05, **p< 0.01, ***p< 0.001 one-way ANOVA with Dunnett’s post-hoc test using Vhcl group as reference (a, b) or two-tailed
Student’s t-test (f–i). Bar, 10 μm (d, g) and 50 μm (e)
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from the Lov-treated mice (Supplementary Fig. 3a) nor when Lov
was added to the cultured 1G11 murine EC line or to 3T3
fibroblasts (Supplementary Fig. 3b, c). In our model, Lov induced
SOD3 mainly in stromal cells in a tumor-specific manner.
Tumor necrosis factor (TNF)-α downregulates SOD3 in 3T3
cells35 and Lov reduces TNF-α expression in tumor-infiltrating
leukocytes33; Lov-induced SOD3 upregulation might be conse-
quence of attenuation of inflammation in the tumor environment.
In support of this idea, Lov reversed TNF-α-induced SOD3
inhibition in vitro in a dose-dependent manner (Supplementary
Fig. 3d). TNF-α-induced SOD3 repression was also reversed by
simvastatin but not by atorvastatin at the highest dose
(Supplementary Fig. 3e). This suggests heterogeneity in the
mechanism by which statins increase SOD3 levels.
Forced SOD3 re-expression potentiates doxorubicin effect.
Statins are pleiotropic drugs with many effects on the vasculature
and/or tumor cell growth36. To link SOD3 directly to Doxo
effectiveness, we injected a recombinant adenovirus (Ad-mSOD3)
to overexpress murine SOD3 in LLC tumors grafted into
SOD3−/− mice; these experiments were done with no Lov
co-treatment. Compared to the weak SOD3 staining in Ad-C
(β-galactosidase-encoding)-injected tumors, Ad-mSOD3 injec-
tion notably increased SOD3 staining in tumor and stromal cells
(Fig. 1g). Owing to the ability of Ad-mSOD3 to infect both tumor
and stromal cells, SOD3 production was distributed homo-
geneously throughout the tumor parenchyma. In the absence of
Doxo, Ad-mSOD3- and Ad-C-injected tumor growth was com-
parable (Supplementary Fig. 4a), which suggested that SOD3
overexpression had no inherent protumor or antitumor activity.
Ad-mSOD3 injection nonetheless enhanced the Doxo inhibitory
effect on tumor growth (Fig. 1h), which again correlated with
higher Doxo levels in Ad-mSOD3- compared to Ad-C-injected
tumors (Fig. 1i). Pharmacological or genetic SOD3 upregulation
in the tumor environment thus increased levels of the small
compound Doxo in tumors.
Intratumor SOD3 levels regulate EC structure and function.
We tested whether SOD3 upregulation altered perfusion of the
tumor parenchyma. Blood vessel labeling with fluorescein
isothiocyanate (FITC)-conjugated lectin showed that Ad-mSOD3
treatment increased the percentage of lectin+CD31+ vessels
compared to Ad-C (Fig. 2a, Supplementary 4b), which implicates
SOD3 directly in promoting tumor perfusion. Despite increased
perfusion in Ad-mSOD3-injected tumors, we noted an unanti-
cipated reduction in blood vessel number (Fig. 2b). Mean vessel
area was nonetheless increased (Fig. 2c), which implied greater
tumor irrigation. Analysis of CD31 staining in thick sections from
Ad-C- and Ad-mSOD3-injected tumors (Fig. 2d) showed that
SOD3 overexpression increased vessel length and diameter
(Fig. 2e, f), although vessel branching was unaffected (Fig. 2g).
We also observed an increase in the percentage of vessels
double stained with lectin and CD31 in Lov- compared to Vhcl-
treated WT mice (Fig. 2h). When Lov and Doxo treatments were
combined, perfusion also increased in WT mice (Supplementary
Fig. 4c). In SOD3−/− mice, Lov treatment did not significantly
enhance tumor perfusion compared to Vhcl, although there was a
clear trend toward a higher percentage of lectin+CD31+ vessels in
these mice (Fig. 2h). Lov treatment might thus have additional,
SOD3-independent effects on tumor perfusion, possibly linked to
its pleiotropic activities on the endothelium. Analysis of lectin+
vessels in thick sections from Vhcl- and Lov-treated tumors
(Fig. 2i) indicated that, as observed in Ad-mSOD3-injected
tumors, Lov treatment of WT mice increased mean vessel area
and tumor vessel length (Fig. 2j, k), although blood vessel
diameter decreased compared to Vhcl-treated mice (Fig. 2l).
These differences were not observed in tumors from Lov- and
Vhcl-treated SOD3−/− mice, which indicates SOD3 influence on
these changes. Vessel branching was comparable in all mice.
Scanning electron microscopy (SEM) suggested that Lov
treatment altered vessel ultrastructure in tumors grown in WT
mice, as lumens were smoother than those in Vhcl-treated WT or
Lov-treated SOD3−/− mice (Fig. 2m). Lov treatment reduced
tumor vessel leakage (dextran extravasation) in WT compared to
Vhcl-treated but not in SOD3−/− mice (Fig. 2n, o). Alteration in
VEC expression is sufficient to disrupt EC intercellular
junctions1. Lov-treated tumors in WT mice had higher VEC
mRNA and protein levels than tumors from Vhcl-treated WT or
Lov-treated SOD3−/− mice (Fig. 2p–r). The extension of VEC
junctions increased in tumor vessels from Lov- compared to
Vhcl-treated WT mice (4.7± 0.5 μm vs. 3.1± 0.2 μm; p< 0.05,
two-tailed Student’s t-test; n = 55). This was not observed in
SOD3−/− mice (Vhcl, 3.8± 0.3 μm, n = 83; Lov, 3.1± 0.2 μm, n =
38).
VEC-stained area in CD31+ structures was larger in
Ad-mSOD3- than in Ad-C-injected tumors (Supplementary
Fig. 4d,e). Ad-mSOD3 also enlarged the extension of VEC
junctions compared to Ad-C (Ad-mSOD3, 7.1± 1.6 μm, n = 50;
Ad-C, 2.9± 0.5 μm, n = 81; p< 0.05, two-tailed Student’s t-test),
which indicates that SOD3 directly regulates VEC expression in
tumor-associated ECs.
SOD3 upregulation in ECs enhances intratumor Doxo levels.
We analyzed whether specific endothelial SOD3 expression
enhanced tumor response to chemotherapy. To generate a con-
ditional mouse strain, we crossed a loxP-SOD3KI mouse line
(Fig. 3a) with an EC-specific inducible Cre-driver line (VE-Cad-
CreERT2)37. Isogenic littermates, Cre+ (SOD3 overexpression in
EC; SOD3EC-Tg) or Cre− (no ectopic SOD3 expression), were
inoculated with LLC cells, and EC-SOD3 overexpression was
induced by two tamoxifen injections; higher tamoxifen doses
impaired tumor angiogenesis, independently of SOD3 induction.
Tamoxifen induced strong SOD3 expression in ~50% of tumor
vessel ECs in Cre+ but not in Cre− mice (Fig. 3b). The Doxo
antitumor effect was greater in SOD3EC-Tg than in Cre− litter-
mates (Fig. 3c), and intratumor Doxo levels were higher in
SOD3EC-Tg mice (Fig. 3d). The percentage of lectin-perfused
blood vessels was higher in SOD3EC-Tg tumors compared to
controls (Fig. 3e, f), which suggested improved tumor perfusion
after EC-SOD3 expression. Analysis of CD31 indicated that EC-
SOD3 expression reduced the total number of CD31-stained
vessels (Fig. 3g, h), although the vessel-covered area was larger in
SOD3EC-Tg tumors (Fig. 3i). SOD3EC-Tg tumor vessels were larger
and of greater diameter than those in control mice (Fig. 3j, k),
whereas vessel branching was unaffected by SOD3 (Fig. 3l).
The VEC-stained area relative to that of CD31 (Fig. 3m, n) and
the extension of VEC junctions also increased in SOD3EC-Tg
vessels compared to controls (SOD3EC-Tg, 2.7± 0.4 μm, n = 83;
Cre−, 1.5± 0.1 μm, n = 130; p< 0.05, two-tailed Student’s t-test).
The reduced dextran-red leakage in SOD3EC-Tg vessels (Fig. 3o)
also suggests a tighter EC barrier. Specific EC-SOD3 expression is
sufficient to improve the LLC tumor response to chemotherapy
and to increase EC barrier firmness.
SOD3 induces VEC expression via a NO-dependent pathway.
We studied the mechanism by which SOD3 stimulates VEC gene
transcription. The microvascular 1G11 endothelial cell line38 was
transduced with a bicistronic retrovirus expressing green
fluorescent protein (GFP) and SOD3. Enhanced SOD3 expression
was verified by immunoblot of lysates from stable mock and
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SOD3 transfectants (Supplementary Fig. 5a), although most
SOD3 was secreted to the medium (Supplementary Fig. 5b).
Dihydroethidium oxidation, used to measure ·O2− levels, was
lower in 1G11-SOD3- than in 1G11-mock-transduced cells, both
in basal culture and after incubation with tumor cell-conditioned
medium, a stress condition that boosted ·O2− production in
mock-transfected cells (Supplementary Fig. 5c). 1G11-SOD3 cells
thus overexpress enzymatically functional SOD3.
SOD3 overexpression in 1G11 cells upregulated VEC expres-
sion compared to mock cells, as detected by immunoblot and
reverse transcriptase quantitative PCR (RT-qPCR) (Fig. 4a, b);
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immunofluorescence (IF) (Fig. 4c). Quantification of continuous
and discontinuous AJ39 indicated that SOD3 increased the
percentage of continuous VEC junctions (Fig. 4d) and reduced
the number of intercellular gaps (Fig. 4e); these data suggest that
SOD3 promotes EC interconnectivity. Permeability to dextran-
FITC particles was lower in 1G11-SOD3 monolayers (Fig. 4f),
which supports a role for SOD3 in vascular integrity. Over-
expression of the inactive SOD3S195C mutant40 did not reduce
1G11 permeability (Fig. 4f), although mutant and WT enzyme
expression were comparable (Fig. 4g). These results indicate the
need for SOD3 enzyme activity to regulate EC permeability.
SOD3 silencing in 1G11 cells reduced VEC expression, as
detected by IF (Supplementary Fig. 6a–d). This reduction in VEC
levels was associated with increased dextran-FITC permeability of
SOD3-silenced 1G11 cell monolayers compared to controls
(Supplementary Fig. 6e).
To further test whether SOD3 increased barrier stability, we
analyzed permeability to dextran-FITC particles in VEGF-treated
1G11-SOD3 and mock cells. In accordance with its leakiness-
inducing activity, VEGF increased permeability in 1G11-mock
monolayers; this did not occur in 1G11-SOD3 cells (Fig. 4h).
VEC staining (Fig. 4i) indicated that VEGF-treated mock cells
showed a reduction in the length of continuous VEC junctions
(Fig. 4j) and an increase in intercellular gaps (Fig. 4k); VEGF
minimally affected these parameters in 1G11-SOD3 cells. The
SOD3-induced increase in VEC expression thus counteracted
VEGF-induced vessel leakiness.
SOD3 scavenging activity increases NO availability24;
fluorescence-activated cell sorting (FACS) analysis of the NO
probe DAF2 showed higher intracellular NO levels in 1G11-
SOD3 than in -mock cells (Fig. 4l, m). Analysis of NO
distribution using the NO-sensitive probe 4,5-diamino-rhoda-
mine B (DAR-1) in LLC tumors indicated that SOD3 induction
by Lov increased DAR-1-associated fluorescence (formed after
the NO reaction) near vascular structures in tumors from WT but
not from SOD3−/− mice (Fig. 4n). A total of 76% of FITC-lectin+
structures in WT tumors (n = 46) showed more intense DAR-1
staining than in adjacent parenchyma, whereas strong DAR-1
staining was seen in only 50% of SOD3−/− tumor vessels (n = 34;
p = 0.016, Pearson’s χ2). These differences in the DAR-1 staining
pattern cannot be attributed to a differential host-dependent Lov
effect on NO synthesis, since endothelial NO synthetase (eNOS)
expression in tumor-associated vasculature was comparable in
Lov-treated WT and SOD3−/− mice (Fig. 4o), also observed in
WT and SOD3−/− mice in basal conditions (Supplementary
Fig. 1). SOD3 levels might influence perivascular NO levels
in vitro and in vivo.
To further analyze the role of NO in the SOD3-mediated
increase in EC barrier function, we treated 1G11-mock and
-SOD3 cells with the NOS inhibitor L-NMMA prior to
permeability analysis. Whereas Vhcl-treated 1G11-SOD3 mono-
layers were less permeable than those of 1G11-mock cells, L-
NMMA treatment increased 1G11-SOD3 permeability to levels
similar to controls (Fig. 4p). Moreover, whereas SOD3 over-
expression in 1G11 cells increased luciferase activity driven by a
~2.5 kb VEC promoter, L-NMMA treatment reduced SOD3-
induced VEC promoter activity to control levels (Fig. 4q). To
confirm NO as a direct regulator of VEC transcription, we
incubated VEC-luciferase reporter-transfected 1G11 cells with the
NO donor (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)
amino] diazen-1-ium-1,2-diolate (DETA-NONOate). Low
DETA-NONOate doses increased VEC promoter-driven lucifer-
ase activity compared to Vhcl-treated cells, whereas very high
DETA-NONOate concentrations inhibited VEC-driven tran-
scription (Fig. 4r). In accordance with this biphasic NO effect
on VEC promoter activity, low and high DETA-NONOate
concentrations had opposite effects on 1G11 permeability to
dextran-FITC (Fig. 4s). A dose-dependent NO-mediated mechan-
ism thus appears to underlie SOD3-induced VEC transcription
and EC barrier stability in 1G11 cells.
SOD3 overexpression in human dermal microvasculature-
derived EC (HDMEC) and in bovine aortic EC (BAEC) also
increased VEC mRNA and protein levels and reduced perme-
ability to dextran-FITC in a NO-dependent manner (Supple-
mentary Fig. 7). SOD3 effects on VEC expression and the EC
barrier are therefore not restricted to mouse-derived ECs or due
to clonal artifacts.
HIF-2αmediates SOD3 enhancement of VEC transcription. To
identify the transcription factor involved in SOD3 induction of
VEC transcription, we analyzed a series of truncated VEC pro-
moters in mock- and SOD3-transfected 1G11 cells. SOD3
potentiated transcription driven by ~2.5 and ~1 kb VEC pro-
moters but not of those <0.5 kb (Fig. 5a), which indicated critical
SOD3 regulatory elements at the −500/−1000 region. This region
has three hypoxia response elements (HRE) and one KLF-4-
binding site (Fig. 5b). HRE are HIF-1 and HIF-2 consensus
binding sites. Only HIF-2α overexpression induced VEC
promoter-driven transcription of a reporter gene (Supplementary
Fig. 8a, b). These results support the reported specific HIF-2α role
in VEC transcription14. Chromatin immunoprecipitation (ChIP)
with anti-HIF-2α and -KLF-4 antibodies showed SOD3-induced
association of HIF-2α (but not KLF-4) to the VEC promoter
−500/−1000 region (Fig. 5c, ChIP2); HIF-2α or KLF-4 interaction
at more distal promoter sites was nonetheless SOD3 independent
(Fig. 5c, ChIP1).
Using directed mutagenesis, we determined the role of each
HRE in the region critical for SOD3-induced VEC transcription.
Elimination of the HRE1 site did not alter SOD3-mediated
Fig. 2 SOD3 upregulation alters tumor-associated vasculature. a Lectin-FITC-perfused, CD31-stained vessels in Ad-C and Ad-mSOD3-injected tumors
(tumor size 0.5–1.2 cm3). Data are shown as the percentage of CD31+lectin+ vessels relative to total CD31+-stained vessels. See also Supplementary Fig. 4b
for representative images. b, c Density (b) and mean area (c) of CD31+ structures in Ad-C- and Ad-mSOD3-injected tumors at end point. d CD31 staining
(red) of sections from Ad-C- and Ad-mSOD3-injected LLC tumors. e–g Determination of the mean length (e), diameter (f), and branches per vessel (g) from
images as in d (n≥ 60 vessels/condition). h Percentage of CD31+lectin+ vessels relative to total CD31+-stained vessels in Vhcl- and Lov-treated LLC tumors
(1–2.5 cm3) grafted into WT and SOD3−/− mice. i Reconstruction of tumor blood vessels from Vhcl- or Lov-treated, lectin-perfused WT and SOD3−/− mice
using the Imaris software (tumor sections 50 μm). jMean vessel area in tumors from Vhcl- and Lov-treated WT and SOD3−/− mice determined from images
stained with anti-CD31 antibody. k, l Determination of mean length (k) and diameter (l) of CD31-stained tumor vessels from Vhcl- or Lov-treated WT and
SOD3−/− mice (n≥ 70 vessels/condition). m Scanning electron microscopic analysis of blood vessels in tumors from Vhcl- and Lov-treated WT and SOD3
−/− mice dissected at day 20 (tumor size <1 cm3). n Vessel leakiness in LLC tumors dissected at day 16 (size <1 cm3), determined by FITC-lectin and Texas
Red-dextran injection, with two-color merge (yellow). o Vessel permeability of samples as in n, determined as the ratio of fluorescence intensity of
extravasated dextran to perfused vessel counts. p Determination of VEC mRNA levels, normalized to those of CD31 (EC marker), in tumors from Vhcl- and
Lov-treated WT and SOD3−/− mice. q Images of VEC (red) and CD31 (green) staining in tumors from Lov-treated WT or SOD3−/− mice dissected at day 20.
Bottom panels show only VEC staining in a magnified area. r VEC-stained area, determined as a percentage of VEC staining in CD31+ structures, in images as
in q. In all cases, 10–20 images were analyzed from ≥5 mice/group; *p< 0.05, **p< 0.01, ***p< 0.001; two-tailed Student’s t-test. Bar, 50 μm
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enhancement of VEC promoter-driven activity, whereas mutation
of HRE2 or HRE3 sites was sufficient to abolish the SOD3
transcription effect (Fig. 5d). These results identify SOD3 as a
positive regulator of HIF-2α-mediated VEC transcription,
probably by fostering HIF-2α association to HRE2 and
HRE3 sites on the VEC promoter.
To further link HIF-2α to SOD3-induced VEC transcription,
we used short hairpin RNA (shRNA) to stably silence this factor
in 1G11 cells (Fig. 5e). HIF-2α knockdown reduced VEC mRNA
levels in 1G11 cells (Fig. 5f); VEC levels in HIF-1α-silenced cells
were unchanged (Supplementary Fig. 8c, d), which supports a
specific HIF-2α role in VEC transcription. SOD3 also activated
the VEC promoter (1 kb) in shNT-1G11 (control) but not in
shHIF-2α-silenced cells (Fig. 5g), which indicates that SOD3-
induced VEC promoter activity is HIF-2α dependent. SOD3
increased luciferase activity driven by a synthetic promoter
bearing 9× HRE sites (Supplementary Fig. 9a), which pinpoints
SOD3 as a general activator of HIF-2α-mediated transcription.
SOD3 stabilizes HIF-2α by curbing PHD activity. We exam-
ined how SOD3 regulates HIF-2α activity. SOD3 overexpression
did not appreciably change HIF-2α mRNA (Supplementary
Fig. 9b) but increased HIF-2α protein levels (Fig. 6a). SOD3 not
only augmented total HIF-2α staining but also increased the area
and intensity of HIF-2α-stained nuclei in 1G11 (Fig. 6b–d) and in
HDMEC (Supplementary Fig. 9c–e). Gradual HIF-2α over-
expression triggered proportional VEC transcription (Supple-
mentary Fig. 9f). SOD3-induced HIF-2α stabilization might thus



























































































































































































































Fig. 3 EC-specific SOD3 expression is sufficient to increase Doxo effect. a Conditional expression allele for the SOD3-IRES-GFP gene at the ROSA26 locus.
b SOD3 (green) and CD31 (red) detection in sections from tumors grown in Cre-expressing and Cre− mice after tamoxifen induction. c LLC tumor growth
kinetics in SOD3EC-Tg and control (Cre−) mice. Arrows indicate tamoxifen and Doxo treatments (n= 10/group). d Doxo quantification in extracts of tumors
dissected at day 16 from control and SOD3EC-Tg mice (n= 15 or 17 mice/group). e, f Images and quantification of lectin-FITC-perfused and CD31-stained
vessels in control and SOD3EC-Tg tumors (0.7–1.2 cm3) dissected at day 20. g CD31 staining of control and SOD3EC-Tg tumors at end point. h–l CD31+
structure density (h), mean area covered by CD31+ structures (i), mean vessel length (j) and diameter (k), and the number of vessel branches (l),
determined in images as in g. m CD31 (green) and VEC (red) staining of tumors grafted in SOD3EC-Tg and control mice. Bottom panels show red staining in
a magnified area. n Quantification of the VEC area in CD31+ structures from images as in m. o Vessel permeability determined by FITC-lectin and Texas
Red-dextran in tumors dissected at day 17 from control and SOD3EC-Tg mice. For b, e–o, 10–20 images were analyzed from 5 mice/group; *p< 0.05, **p<
0.01, two-tailed Student’s t-test. Bar, 50 μm
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03079-1 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:575 |DOI: 10.1038/s41467-018-03079-1 |www.nature.com/naturecommunications 7
As NO negatively regulates PHD activity17, we tested whether
SOD3 regulates HIF-2α posttranslationally. Levels of PHD-2 (the
most abundant isoform) were comparable in 1G11-SOD3 and
-mock cells (Supplementary Fig. 9g), which suggested that SOD3
does not affect PHD abundance. The selective PHD-2 inhibitor
IOX241 increased VEC promoter-driven luciferase activity in
1G11-mock vs. Vhcl-treated cells but did not induce higher VEC
promoter activity in 1G11-SOD3 cells than that observed after
SOD3 overexpression (Fig. 6e); this implies that IOX2 and SOD3
act on the same pathway to boost VEC promoter-driven
transcription.
To quantify PHD activity in mock- and SOD3-transfected cells,
we established an enzyme-linked immunosorbent assay (ELISA)
to detect proline hydroxylation of a peptide from the HIF-1α
oxygen-dependent degradation domain, with recombinant HA-
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and non-hydroxylated HIF-1α peptides (Supplementary Fig. 9h),
which confirmed ELISA specificity. SOD3 overexpression reduced
peptide hydroxylation (Fig. 6g), which was associated with
reduced HIF-2α ubiquitination in 1G11-SOD3 cultured in
normoxia (Fig. 6h). HIF-2α degradation was delayed after re-
oxygenation of hypoxic cultured 1G11-SOD3 compared to mock
cells (Fig. 6i, j); oxygen-induced HIF-1α degradation was
unaffected by SOD3 overexpression (Supplementary Fig. 9i, j).
Our data showed more rapid HIF-1α decay after re-oxygenation
than HIF-2α, which agrees with differential HIF-1α and HIF-2α
sensitivity to oxygen-induced breakdown in ECs12. The degree of
SOD3-induced PHD inhibition might be insufficient to prevent
this rapid HIF-1α degradation.
The nuclear HIF-2α-stained area and intensity were reduced in
L-NMMA- than in Vhcl-treated 1G11-SOD3 cells (Fig. 6k–m),
which implicates NO in SOD3-mediated HIF-2α stabilization.
DETA-NONOate treatment increased VEC promoter-driven
luciferase activity in HIF-2α- but not in mock-transfected 3T3
fibroblasts (Supplementary Fig. 9k). As 3T3 cells in normoxia do
not express HIF-2α, our data indicate that NO induces VEC
promoter-driven transcription by regulating HIF-2α levels.
HIF-2α ablation in EC impedes SOD3 effects on Doxo activity.
To confirm the role of endothelial HIF-2α in mediating SOD3
effects on tumor vasculature, we analyzed the result of SOD3
overexpression on Doxo effectiveness in mice lacking HIF-2α in
ECs (HIF-2αEC-KO), obtained by crossing HIF-2αf/f42 with VE-
Cad-CreERT2 mice. HIF-2α and VEC mRNA levels were reduced
in EC isolated from tumors grafted in HIF-2αEC-KO mice vs. Cre−
littermates after tamoxifen injection (Supplementary Fig. 10a, b),
which supports HIF-2α as a VEC regulator in tumor
endothelium.
To determine whether the improved, SOD3-induced response
to chemotherapy is HIF-2α dependent, we injected Ad-C or Ad-
mSOD3 virus and Doxo into tumor-bearing tamoxifen-treated
HIF-2αEC-KO or Cre− mice. Coinciding with our earlier data
(Fig. 1h), Ad-mSOD3 increased Doxo activity in controls
compared to Ad-C treatment (Fig. 7a), while the Ad-mSOD3
effect was lost when LLC tumors were grafted into HIF-2αEC-KO
mice (Fig. 7b). SOD3 overexpression improved perfusion of
tumors implanted in control but not in HIF-2αEC-KO mice
(Fig. 7c, d). Ad-mSOD3-injected tumors in controls but not in
HIF-2αEC-KO mice reduced blood vessel number (Fig. 7e) but
increased the tumor area covered by vessels as well as their length
and diameter (Fig. 7f–h); the branching pattern was unaffected
(Fig. 7i). The SOD3-mediated increase in VEC mRNA and
protein levels in controls was not observed in HIF-2αEC-KO
mouse tumors (Fig. 7j, k; Supplementary Fig 10c–f). The data
indicate that HIF-2α is central to SOD3-induced VEC
transcription and enhanced Doxo antitumor activity. Our results
suggest that SOD3 improves tumor vascular function by
augmenting HIF-2α-dependent VEC expression, probably by
increasing NO availability and thus inhibition of PHD activity.
SOD3 correlates with VEC and HIF-2α levels in human can-
cers. We next measured SOD3 and VEC mRNA levels in freshly
frozen samples from a cohort of 102 colorectal carcinoma (CRC)
patients (stages I–IV) and in non-tumor samples >10 cm from
the primary tumor in the same patients. We found lower SOD3
and VEC mRNA levels in CRC than in non-tumor samples
(Fig. 8a, b), with a positive correlation of levels for these genes in
CRC samples (Fig. 8c). SOD3 mRNA reduction was not asso-
ciated to a specific stage or CRC molecular subtype43.
To further study this SOD3/VEC association, we analyzed an
independent validation cohort comprised of 87 CRC stage III and
19 non-tumor samples. SOD3 and VEC mRNA levels were again
lower in CRC than in non-tumor samples (Fig. 8d, e), with
positive correlation between these genes in tumor samples
(Fig. 8f). The results thus suggest SOD3 and VEC coregulation
in CRC.
Since SOD3 regulates HIF-2α posttranscriptionally in mouse
ECs, we tested the association between SOD3 and HIF-2α by
immunohistochemistry (IHC) in the epithelial tumor cell
compartment and tumor-associated stroma, using a tissue
microarray (TMA) of 89 CRC samples (stages I–IV; Fig. 8g);
23.6% of tumor and 8.2% of stromal samples showed no SOD3 or
HIF-2α staining. We estimated separate H-scores for each marker
in each tumor area; values correlated positively for SOD3 and
HIF-2α in stroma (Fig. 8h) and negatively in the tumor
compartment (Fig. 8i). SOD3 and HIF-2α might thus be
regulated distinctly in epithelial and stromal cells.
As SOD3 regulated HIF-2α stability in mouse EC, we studied
the expression of these two genes in the CRC TMA, using CD34
as a label of tumor-associated ECs; 55.4% of CD34+ ECs were
SOD3 stained (Fig. 8j; Supplementary Fig. 11). Some sections
showed adjacent SOD3-stained and unstained ECs, which implies
that this pattern was not artifactual. Most SOD3-stained ECs also
showed nuclear HIF-2α accumulation (97.6%). These data
suggest that SOD3 stabilizes HIF-2α in human tumor-
associated ECs, similar to observations in our mouse tumor
models.
Discussion
The success of chemotherapy relies on the delivery of sufficient
amounts of cytotoxic drugs to kill tumor cells. Progressing tumors
have aberrant, hyperpermeable vasculature, which reduces tumor
perfusion and restricts diffusion of small molecules from the
bloodstream to the tumor interstitial space2,3. Here we identify
Fig. 4 SOD3-induced VEC expression requires SOD3 enzyme activity and NO. a VEC and tubulin (loading control) levels in 1G11-mock- and -SOD3-
transduced cells. The VEC/tubulin ratio is indicated (n= 3). b VEC mRNA normalized to CD31 levels in mock and SOD3-expressing cells (n= 5). c VEC
staining (red) in 1G11-mock- and 1G11-SOD3-transduced cells. Nuclear staining with DAPI (blue) (n> 20 fields/condition). d Continuous vs. discontinuous
junctions expressed as junction length (% total junction length) in mock and SOD3-expressing cells. e Gap index in confluent cells as in c. (d, e, n≥ 5
fields/condition). f FITC-dextran (40 kDa) permeability of 1G11-mock, -SOD3 and -SOD3S195C cell monolayers (n= 3). g SOD3 levels in cells as in f;
bottom, filter rehybridized with actin. SOD3/actin ratio indicated (n= 3). h FITC-dextran permeability of 1G11-mock and -SOD3 monolayers, untreated or
VEGF-pretreated (n= 9). i VEC staining of untreated and VEGF-treated cells as in h. j, k Continuous vs. discontinuous junctions (j) and gap index (k) in
VEGF-treated and untreated cells; n≥ 5 fields/condition. l FACS analysis of DAF2 staining in 1G11-mock and -SOD3 cells. Non-specific staining (gray). m
DAF2 intensity from cells as in l (n= 3). n NO distribution in LLC tumors from Lov-treated WT and SOD3−/− mice, visualized by DAR-1, microangiography
using FITC-lectin, merge of DAR-1, FITC-lectin, and DAPI counterstaining, and pseudocolor representation of DAR-1 microfluorographs. Arrowheads
indicate large blood vessels. Images are confocal microscopy z-stacks. o eNOS detection in sections from tumors as in n. p FITC-dextran permeability of L-
NMMA- or Vhcl-pretreated 1G11-mock and -SOD3 monolayers (n= 6). q VEC promoter activity in L-NMMA- or Vhcl-treated 1G11 cells (n= 5). r VEC
promoter activity in DETA-NONOate- or Vhcl-treated 1G11 cells (n= 9). s FITC-dextran permeability of DETA-NONOate-pretreated 1G11-mock and -SOD3
monolayers; 0=Vhcl (n= 9). Data shown as mean± SEM. *p< 0.05, **p< 0.01, ***p< 0.001; two-tailed Student’s t-test (b, d, e, k, m, p–r) or ANOVA
with Dunnett’s (f, s) or with Tukey’s (h, j) post-hoc tests. Bar, 5 μm (c) and 25 μm (i, n)
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SOD3 upregulation as a target for improving tumor perfusion
and selective Doxo delivery through increased VEC transcription
via HIF-2α. Elevated SOD3 levels, but not those of a catalytically
inactive mutant, reduced monolayer permeability and prevented
the VEGF-induced destabilization of AJ. Specific HIF-2α ablation
in EC prevented these SOD3 activities, which suggests HIF-2α as
a critical SOD3 mediator in vivo.
Reports are contradictory regarding SOD3 influence on tumor
progression and angiogenesis. SOD3 not only mediates VEGF-C-
induced angiogenesis and metastasis in a specific breast cancer
subset44 but also inhibits angiogenesis by reducing VEGF-A
expression45 or release from the extracellular matrix46. A positive
feedback loop between Ras activation and SOD3 is suggested to
boost cancer cell proliferation26,47, although SOD3 is down-
regulated via transcriptional29,30 and posttranscriptional
mechanisms48 in a number of human cancers. We found SOD3
mRNA downregulation in two independent CRC cohorts com-
pared to healthy colon tissue, which coincides with low SOD3
protein levels in CRC biopsies32. SOD3 silencing thus appears to
be common in several malignant tumors.
We used three approaches to upregulate SOD3 in the in vivo
tumor environment, one pharmacological (Lov administration)
and two genetic (intratumor Ad-mSOD3 injection and EC-
specific inducible SOD3 expression). Statins are pleiotropic drugs
that can affect the endothelium through various mechanisms36.
Given that Lov did not improve Doxo delivery or induce VEC
expression in tumors implanted in SOD3−/− mice, these Lov
effects could be considered SOD3 dependent. Lov upregulated
SOD3 significantly in ECs and leukocytes isolated from LLC
tumors implanted in WT hosts but not in ECs and leukocytes
from tumor-free organs from these mice. These data indicate that
Lov upregulates SOD3 in stromal cells via an indirect mechanism
that operates in the tumor microenvironment. Our results show
that Lov and simvastatin reversed the TNF-α-induced inhibition
of SOD3 expression; these statins might thus induce SOD3 by
attenuating inflammation. Atorvastatin, added alone or with
TNF-α, did not increase SOD3 mRNA. Individual statins can
induce specific gene expression profiles, which has been asso-
ciated with their intracellular concentration49. Whether the dis-
parate effects on SOD3 expression between these statins are due
to bioavailability or mechanistic differences requires further
study.
Another pending question is whether SOD3-induced vascular
remodeling depends on its expression in a specific tumor com-
partment. Lov induced SOD3 in ECs and leukocytes. SOD3
overexpression in ECs was sufficient to increase Doxo effective-
ness and reduce tumor vessel permeability, although we observed
similar effects after intratumor injection of Ad-mSOD3, which
infects and triggers SOD3 expression in tumor and stromal cells.
SOD3 is a soluble, secreted enzyme and hence can diffuse in the
tumor tissue. Elevation of SOD3 to a level that markedly reduces
oxidative radicals in the tumor milieu might thus normalize
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Fig. 5 HIF-2α mediates SOD3-induced VEC transcription. a Relative
luciferase activity (RLU) in 1G11 cells cotransfected with SOD3 (or mock)
and the full-length VEC promoter or deletion mutants. Values were
normalized to the signal in 1G11-mock cells for each promoter (n= 4).
b Full-length (~2.5 kb) VEC promoter with binding sites for the main
transcription factors. Numbers indicate positions relative to the
transcription start site. HRE hypoxia response element, SBS Sox-binding
site, EBS Ets-1-binding site. c ChIP analysis of VEC promoter in mock- and
SOD3-transfected 1G11 cells using anti-HIF-2α and -KLF-4 antibodies.
Coprecipitated DNA fragments were PCR-quantified using primers in a
(arrows; n= 5). d RLU in 1G11-mock or -SOD3 cells transfected with VEC
promoter HRE mutants. The mutated HRE site is indicated (white square; n
= 10). e Immunoblot analysis of control (shNT) and HIF-2α-silenced
(shHIF-2α) 1G11 cells (n= 3). The HIF-2α:tubulin densitometry ratio is
shown (bottom). f VEC mRNA levels, using CD31 as reference, in cells as in
e. g Relative VEC promoter activity in control and shHIF-2α-1G11 cells
transfected with mock or SOD3 plasmids. Data shown as
mean± SEM (b-g). *p< 0.05, ***p< 0.001; two-tailed Student’s t-test
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It is not obvious how an extracellular enzyme might regulate
VEC transcription. SOD3 is not itself a transcription factor but
can reach the nucleus50, as reported for other SODs51. In the
TMA analyses of CRC patients, individual tumor-associated ECs
accumulated intracellular/nuclear SOD3. Nuclear SOD3 protects
DNA from oxidative damage28 and attenuates NF-κB activity by
regulating its oxidative state52. In the case of VEC, we propose
that SOD3 inhibits PHD activity to prevent HIF-2α ubiquitina-
tion and degradation (Supplementary Fig. 12). Since VEC pro-
moter activation is directly proportional to HIF-2α levels
(Supplementary Fig. 9c), SOD3-induced HIF-2α stabilization


































































































































































































































Fig. 6 SOD3 stabilizes HIF-2α posttranscriptionally via NO. a Immunoblot analysis of 1G11-mock and -SOD3 cell extracts with anti-HIF-2α and -tubulin
antibodies (n= 2). The ratio between bands is shown (bottom). b Immunofluorescence analysis of HIF-2α staining in mock and SOD3-expressing cells
(n≥ 500 cells/condition). c, d Percentage of nuclear area and mean fluorescence intensity in images in b. e Relative VEC promoter activity in IOX2- or
Vhcl-treated 1G11-mock and -SOD3 cells. f Scheme of the ELISA used to detect PHD activity. g PHD activity, determined by ELISA, in mock and SOD3-
expressing cell extracts. SOD3 levels are shown in these cells as determined by immunoblot (actin loading control; n= 3). h Top, HIF-2α ubiquitination
analysis in immunoprecipitates of MG132-treated 1G11-mock and -SOD3 cells at the indicated times. Bottom, rehybridization with anti-HIF-2α antibody. i
Immunoblot of HIF-2α in extracts from 1G11-mock and -SOD3 cells cultured in hypoxia (6 h), cycloheximide treated, and cultured in normoxia for the
indicated times. Blots were rehybridized for tubulin as loading control. A representative experiment is shown (n= 4). j Quantification of the HIF-2α/tubulin
densitometry ratio from i, expressed as the percentage of the ratio at time 0 (hypoxic conditions, 100%). k Representative images of Vhcl- or L-NMMA-
treated 1G11-SOD3 cells stained with anti-HIF-2α antibodies. l, m Relative percentage of stained nuclear area and mean fluorescence intensity in Vhcl- or L-
NMMA-treated 1G11-mock and -SOD3 cells. Values were normalized to the lowest value in the Vhcl-treated group for each cell type (n≥ 100 cells/
condition). For a, c–e, g, j, l, m, data shown as mean± SEM from at least three independent experiments. *p< 0.05, **p< 0.01, ***p< 0.001; two-tailed
Student’s t-test (c, e, g, l, m) or two-way ANOVA with Bonferroni post-hoc test (j), showing significant differences between cell lines. Bar, 30 μm
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Fig. 7 Specific HIF-2α ablation in EC abolishes in vivo SOD3 effects. a, b Growth kinetics of Ad-C- or Ad-mSOD3-injected LLC tumors grafted in control
(Cre−; a) or HIF-2αEC-KO mice (b). c, d Images of lectin-FITC-perfused (green), CD31-stained (red) vessels in tumors resected at day 18 (≤1 cm3) from
control and HIF-2αEC-KO mice. e–i Vessel density (e), mean area (f), length (g), diameter (h), and branching (i) determined by CD31+ staining in tumors
from a, b (n≥ 25 fields/condition). j VEC mRNA levels, normalized to those of CD31, in tumors in a, b. k VEC-stained area as a percentage of VEC staining
in CD31+ structures in images of tumors in a, b (see also Supplementary Fig. 10c–f); n= 10–20 images/group. *p< 0.05; **p< 0.01; ***p< 0.001; two-
tailed Student’s t-test. Bar, 50 μm
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transcription. It was not anticipated that SOD3 would trigger
specific HIF-2α binding to the −500/−1000-bp region, in which
no HIF-2α binding was detected in mock cells. SOD3-induced
HIF-2α binding to the VEC promoter might entail not only HIF-
2α stabilization but also local modifications to chromatin struc-
ture. Moreover, since HIF-2α but not HIF-1α transactivates the
VEC promoter, HIF-2α might cooperate with other transcription
partners whose activity or location could be SOD3 influenced.
We propose that SOD3 effects on HIF-2α and VEC
expression depend on increased NO availability due
to ·O2− scavenging. This is based on our observation that (i)
SOD3 activity and NO synthesis were needed to reduce EC
permeability, (ii) NO synthesis blockade reduced and a NO
donor increased HIF-2α-mediated VEC promoter activity, and






















































































































































































CD34 SOD3 HIF-2α DAPIMerge
Fig. 8 Coregulation of SOD3, VEC, and HIF-2α in primary CRC tumors. a, b Scatter plots showing individual data points and mean for SOD3 (a) and VEC
(b) mRNA levels in non-tumor (C; n= 13) and CRC samples (CRC; n= 102). c Correlation of SOD3 and VEC mRNA levels in the CRC cohort. d, e Scatter
plots as above for SOD3 (d) and VEC (e) mRNA levels in a validation cohort of 19 non-tumor and 87 stage III CRC samples. f Correlation of SOD3 and VEC
mRNA levels in the CRC validation cohort. g TMA samples stained for SOD3 and HIF-2α, representative of low (#6) and high (#61) SOD3 levels. h, i
Correlation of estimated H-scores for SOD3 and HIF-2α in stromal (h) and tumor (i) compartments. j Representative images from two tumor samples
stained for CD34 (red), SOD3 (green), and HIF-2α (blue); the three-color merge is shown; nuclei were counterstained with DAPI (see Supplementary
Fig. 11 for single-color images). White lines in the DAPI panel contour CD34-stained areas. c, f, h, i Spearman’s rank correlation test; a, b, d, e *p< 0.05,
two-tailed Student’s t-test. Bar, 50 μm (g) and 20 μm (j)
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NO has contrasting concentration- and time-dependent effects
on EC barrier function. Lack of eNOS reduces VEGF-induced
permeability, suggesting a negative NO role in barrier func-
tion53,54. Inhibition of endothelial NO production nonetheless
accentuates basal and induced alterations in vascular perme-
ability19,55. We also found an inverse, dose-dependent DETA-
NONOate effect, which increased VEC transcription and reduced
EC permeability at low doses, with opposite effects at high doses.
In vivo evidence indicates that perivascular NO accumulation
reduces tumor vasculature permeability18, a phenotype similar to
that of tumors with high SOD3 levels. The NO reaction with ·O2−
can modify its effect on barrier stability20. The NO donor NOC-
18 stabilizes HIF-1α, whereas the NO/·O2− donor SIN-1 pro-
motes its degradation in cerebral ECs; SIN-1 co-addition with
SOD stabilizes HIF-1α in ECs21. Rather than modifying NO
synthesis (eNOS levels are comparable in WT and SOD3−/− EC),
SOD3 might maintain a delicate NO/·O2− balance that improves
EC barrier function and drug delivery.
Although we cannot establish whether the same SOD3/HIF-
2α/VEC regulatory circuit operates in human malignancies,
SOD3 and VEC mRNA levels correlated positively in two inde-
pendent CRC cohorts. This association is indicative of coregula-
tion between these genes in human CRC. We were unable to
confirm this association at the protein level, due to inconsistent
results using anti-human VEC antibodies in IHC. SOD3 and
HIF-2α nonetheless correlated positively in CRC tumor stroma
but were negatively associated in tumor epithelial cells, which
suggests that SOD3 stabilizes HIF-2α specifically in stromal but
not in neoplastic cells. Most SOD3-stained tumor EC showed
HIF-2α staining, whereas unstained ECs lacked HIF-2α. If con-
firmed, the cell type-specific SOD3 effect on HIF-2α levels might
be of therapeutic use, given the antithetical HIF-2α function in
tumorigenesis; its upregulation in cancer cells promotes pro-
liferation and neoangiogenesis15,16 and, in ECs, induces vascular
normalization and enhanced drug delivery12,13.
Some tumors showed adjacent SOD3-stained and unstained
EC, which appears not to be an artifact but to indicate true stromal
heterogeneity. Although SOD3 and NO are diffusible substances
that can spread over short distances, extracellular matrix com-
position and surrounding non-ECs might confine SOD3/NO
dispersion, as for other biomolecules56. A local inflammatory
milieu might also preclude SOD3 expression in specific EC.
In summary, our results identify SOD3 as a regulator of VEC
transcription in tumor vasculature by NO-dependent stabilization
of HIF-2α. This improves perfusion and delivery of chemother-
apeutics into murine tumors. SOD3 and VEC are also co-
regulated in human CRC, although further research is needed to
define SOD3 utility as a predictive biomarker for chemotherapy
effectiveness.
Methods
Plasmids and viral constructs. SOD3 cDNA was obtained from Open Biosystems
and the SOD3S195C mutant was generated by directed mutagenesis (QuickChange
Site-Directed Mutagenesis Kit, Stratagene), using the primers described40. SOD3
and SOD3S195C were subcloned in the pRVIRES-gfp plasmid and retroviruses
produced as described57. SOD3 was also subcloned in the shuttle pCMV vector
(AdEasy Adenoviral Vector System, Stratagene), and high titer stocks of Ad-
mSOD3 and Ad-LacZ were prepared by the Unidad de Producción de Vectores
(Centro de Biotecnología Animal y Terapia Génica, Barcelona, Spain). The mouse
HIF-2α cDNA cloned in pCMVSPORT-6, the shHIF-2α RNA (pGIPZ-mEPAS1
#481932), and a scrambled shRNA (shNT) were obtained from Dharmacon GE
Healthcare. pcDNA3-hHIF1α was provided by Dr. Luis del Peso (Universidad
Autónoma de Madrid, Spain). SOD3 was silenced with pLK0.1shRNASOD3 (clone
ID NM_011435.2-366s1c1; TRCN0000101354) using pLKO-puro Non-Target
(shNT) RNA as control (Sigma-Aldrich).
Cell lines and overexpression/silencing experiments. The murine micro-
vascular 1G11 cell line38 was a gift of A. Mantovani (Humanitas Clinical and
Research Center, Italy) and was cultured on 1% gelatin-coated plates with Dul-
becco’s modified Eagle’s medium (DMEM) containing 20% fetal calf serum (FCS),
2 mM L-glutamine, 1 mM sodium pyruvate, non-essential amino acids, endothelial
cell growth supplement (Sigma-Aldrich), heparin, and antibiotics. Their endothe-
lial origin was verified by VEC staining. Stable 1G11-mock and 1G11-SOD3 cells
were obtained by retroviral transduction with pRVIRES-gfp and pRV-sod3-IRES-
gfp, respectively, followed by cell sorting (MoFlo XDP; Beckman Coulter) using
GFP fluorescent emission. Cell lines were analyzed regularly by FACS for GFP
expression (Cytomics FC500; Beckman Coulter). SOD3 and HIF-2α were silenced
in 1G11 cells with pLK0.1shRNASOD3 (clone ID NM_011435.2-366s1c1;
TRCN0000101354) or the shHIF-2α RNA #481932, respectively, using pLKO-puro
Non-Target (shNT) RNA as control, with Lipofectamine 3000 (Thermo Fisher
Scientific)58. Stable cells expressing each shRNA were obtained after puromycin
selection (2 μg/ml, Clontech). HIF-1α was silenced by transfecting 1G11 cells with
siRNA1 (5′GGGCCGCUCAAUUUAU GAAUAUUAU3′), siRNA2 (5′UACUCA-
GAGCUUUGGAUCAAGUUAA3′), or a mixture of both, using Lipofectamine
2000 (Invitrogen); as non-target control, a medium GC content siRNA duplex was
used (Stealth RNAi siRNA Negative Control Med GC, 12,935,300, Invitrogen).
HIF-1α and VEC mRNA were estimated by RT-qPCR at 48 h posttransfection.
The human dermal microvascular EC line (HDMEC; Cascade Biologics,
Portland, Oregon) was used directly from the provider and cultured on 0.5%
gelatin-coated plates with MCDB131 medium with 10% FCS, 2 mM L-glutamine,
20 mM HEPES, 10 ng/ml human epidermal growth factor (EGF; PeproTech), 30
μg/ml bovine pituitary extract (Invitrogen), 1 μg/ml hydrocortisone (Sigma-
Aldrich), and antibiotics. HDMEC were infected with Ad-hSOD3 (Vector Biolabs)
and Ad-LacZ at the indicated m.o.i. BAEC (Clonetics, Lonza) were cultured on
0.1% gelatin-coated plates with low-glucose DMEM medium with 10% FCS and 2
mM L-glutamine. Other cell lines used were obtained from the ATCC and cultured
as recommended. All cell lines were tested regularly for mycoplasma
contamination. Primary EC from WT and SOD3−/− mice were isolated from the
lung and cultured as described59.
Human samples. Freshly frozen stage I–IV tumor samples (cohort 1) were
obtained from the Hospital Clínico San Carlos Tumor Bank between 2001 and
200643. We also used formalin-fixed paraffin-embedded tumor samples from stage
III CRC patients (cohort 2). For both cohorts, non-tumor samples correspond to
colon tissue obtained at >10 cm from the primary tumor in the same patients.
These normal colon tissue samples were analyzed histologically by hematoxylin/
eosin staining to verify that they did not contain tumor cells; samples in which the
pathologist suspected or observed minimal alterations in colon mucosa were dis-
carded. Appropriate informed consent was obtained from all the patients and no
personal data were registered. The Hospital Clínico San Carlos Ethical Committee
approved this study.
Animals. C57BL/6J mice were obtained from The Jackson Laboratory, and
SOD3−/− mice have been described22. The SOD3 transgenic mice were generated in
collaboration with Ozgene Pty. Ltd. (Bentley WA, Australia). The targeting vector
was composed of the UbiC promoter, a loxP-flanked STOP cassette, a cassette
containing the murine SOD3 cDNA, an IRES sequence, and the GFP cDNA. The
entire vector was sequenced to confirm correct assembly. The targeting vector was
inserted into the ROSA26 locus by homologous recombination, linearized, and
electroporated into C57BL/6J embryonic stem cells. Chimeras were identified and
crossed with C57BL/6J mice to obtain the germline-transmitted heterozygous
floxed mice (loxP-SOD3KI). loxP-SOD3KI mouse founders were confirmed by
DNA genotyping using the primers (fw): 5′GGGAGTGTTGCAATACCTTTCT3′
and (rev): 5′CAGATGACTACCTAT CCTCCCATT3′, which amplify the WT
allele, and (fw): 5′CTGAAGCTCCGGTTTTG AACTATG3′ and (rev): 5′
GCCTTGAGCCTGGCGAACAGTT3′, which amplify the transgenic allele. Mice
with inducible SOD3 expression in EC (SOD3EC-Tg) were achieved by breeding two
different germ-line loxP-SOD3KI founders with VE-Cad-CreERT2 mice37, which
has inducible Cre recombinase expression under the control of a modified VEC
promoter. Tumorigenesis experiments performed with bi-transgenic mouse lines
derived from both loxP-SOD3KI founders yielded similar results. Inducible dele-
tion of HIF-2α in EC (HIF-2αEC-KO) was achieved by crossing HIF-2αf/f42 with
VE-Cad-CreERT2 mice. In all experiments involving SOD3EC-Tg and HIF-2αEC-KO
mice, Cre+ and Cre− littermates were used for tumorigenesis studies. Mouse
experiments were approved by the Comunidad de Madrid (PROEX 399/15) and
the CNB Ethics Committees and carried out with 2–5-month-old female mice in
strict accordance with the Spanish and European Union laws and regulations
concerning care and use of laboratory animals.
Syngeneic tumor models. Adherent growing LLC (>98% live cells) were har-
vested, and single-cell suspensions of 5 × 105 cells in 100 μl phosphate-buffered
saline (PBS) were injected subcutaneously into the right flank of the syngeneic
mouse lines indicated above; only female mice were used. Tumors were measured
periodically with calipers and tumor volume was calculated using the formula V =
width2 × length/2. When tumors reached an average size of 100 mm3, LLC tumor-
bearing mice were randomized for treatment by a technician blind to treatments. In
tumor experiments involving use of statins, mice received one daily intraperitoneal
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(i.p.) injection of Vhcl (5% ethanol) or Lov (15 mg/kg; Sigma-Aldrich) starting at
day 7 after LLC inoculation. In tumor experiments involving use of SOD3EC-Tg and
HIF-2αEC-KO mice, tamoxifen (Sigma-Aldrich) was diluted in ethanol and corn oil,
heated at 100 °C and injected (1 mg/mouse, i.p.) on days 3 and 6 post-LLC
inoculation. Tamoxifen-induced SOD3 overexpression in EC was determined by
immunochemical staining of SOD3 in tumor sections; tamoxifen-induced excision
of HIF-2α was determined by RT-qPCR in purified EC from tumors grafted in
Cre+ and Cre− mice. In tumor experiments involving the use of adenovirus
(SOD3−/− and HIF-2αEC-KO mice), Ad-mSOD3 or Ad-C viruses (109 pfu/50 μl,
intrathecal) were injected on days 7, 9, 11, and 15 after LLC inoculation. For all
tumor models, Vhcl or Doxo (2.5 mg/kg; Farmitalia Carlo Erba, Italy) was admi-
nistered i.p. on days 7, 11, and 15 postimplantation. Tumor volume was measured
blind to treatment or genotype.
For tumor cell fractionation, we used LLC-GFP cells generated by retroviral
transduction of LLC cells with pRV-IRES-GFP; transduced cells were selected by
cell sorting (MoFlo XDP; Beckman Coulter) using GFP fluorescent emission. LLC-
GFP cell in vitro proliferation capacity was similar to parental LLC cells. Tumors
were generated by subcutaneous injection of LLC-GFP cells and mice were treated
with Vhcl or Lov as above; at day 21, tumors, lungs and spleen were excised.
Tumors were digested (16 h, 37 °C) in DMEM/F12 (1:1) with collagenase (300 U/
ml)/hyaluronidase (100 U/ml) (Stem Cell Technologies) and DNase I (Roche).
Digestion was terminated by addition of HBSS (Gibco) with 10 mM HEPES and
2% FCS60. The resulting single-cell suspensions were stained with anti-CD45-APC
(clone 30-F11, eBioscience) and anti-CD31-PE antibodies (clone MEC13.3, BD
Pharmingen); EC (CD31+), hematopoietic (CD45+) and LLC-GFP cells were
isolated by cell sorting. Isolated cells were used for SOD3 mRNA quantification
(see below). ECs were isolated from the lungs of these mice, as described59. After
erythrocyte lysis, hematopoietic cells from mechanically disrupted spleens of
tumor-bearing mice were isolated by positive selection of CD45+ cells with sheep
anti-rat magnetic beads (Invitrogen) precoated with the anti-CD45 antibody. Lungs
and spleen showed no macroscopic or microscopic signs of metastasis.
Doxo quantification. Intratumor Doxo levels were quantified blindly in tumor
extracts 1 day after the last Doxo dose, using high-performance liquid chroma-
tography coupled to fluorescence detection, with daunorubicin as internal
standard33.
qPCR of human and mouse genes. Total RNA was extracted from mouse tumors,
isolated cells from tumors and healthy organs, and cell lines, using Tri-Reagent
(Sigma Aldrich) and RNEasy Mini or Micro Kit (Qiagen). RNA from frozen
human samples was extracted using TRIZOL (Invitrogen, Carlsbad, CA) and from
human formalin-fixed paraffin-embedded tumor samples using the RNeasy FFPE
Kit (Qiagen). RNA was treated with DNAse (RNeasy Microkit, Qiagen) and
quantified with a NanoDrop ND-1000 (Thermo Scientific). RNA quality was
determined with an Agilent Bioanalyzer 2100 (Agilent Technologies). First cDNA
strand was synthesized from 0.2–2 μg total RNA (High-capacity cDNA Archive
Kit, Applied Biosystems), using random primers. mRNA levels for SOD3, CD31,
VEC, DLL4, eNOS, FLT1, ICAM1, VCAM1, ROBO4, TIE2, VEGF-A, NOTCH1,
NOTCH2, NOTCH4, HIF-1α, and HIF-2α were quantified in an ABI PRISM
7900HT System (Applied Biosystems), using a SYBR Green-based reaction mix
(FluoCycle; EuroClone), with the primers listed in Supplementary Table 1. β-Actin
(mouse samples) and RPL10A genes (human samples) were used for normalization
except for VEC mRNA analyses, which were normalized with CD31 mRNA levels.
Values for each gene are expressed as relative quantity (Rq), calculated as 2−ΔΔCt
relative to the sample with the lowest expression.
SOD3 induction in cultured cells. For in vitro experiments, Lov was activated as
described61. 3T3 cells were serum depleted (24 h) before incubation with TNF-α
(10 ng/ml; Peprotech) and various doses of activated Lov, simvastatin, or ator-
vastatin (both 1 μM; Calbiochem) or their vehicles. Media was refreshed every 24 h
with TNF-α and statins. Cells were lysed after 48 h and RNA was extracted as
above.
Immunoblot. Tumor and cell extracts were prepared with RIPA buffer, proteins
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotted with rabbit anti-SOD3, rabbit anti-VEC, mouse anti-
pan-cadherin (H-19, Sigma Aldrich), rabbit anti-HIF-2α (NB100-122, Novus
Biologicals, or ab109616, Abcam), rabbit anti-HIF-1α (PA1-16601, Thermo Fisher
Scientific), or rabbit anti-PHD2 (#4835, Cell Signaling); mouse anti-β-actin,
-tubulin (Sigma Aldrich), or -GAPDH (clone 6C5, Abcam) were used for loading
controls. Mouse lung or kidney extracts were used as positive controls for SOD3.
For HIF-2α ubiquitination analyses, 1G11-mock and -SOD3 cells in exponential
growth were treated with the proteasome inhibitor MG132 (1 μM; S2619, Sell-
eckchem) for 8 or 16 h. Cells were lysed in RIPA buffer supplemented with 1%
SDS, 20 μM NEM (N-ethylmaleimide; Sigma-Aldrich), and a complete Mini Pro-
tease Inhibitor Cocktail (Roche); total lysates (250 μg) were immunoprecipitated
with 2 μg rabbit anti-HIF-2α antibody (sc 28076, Santa Cruz Biotechnology) and
protein A/G magnetic beads (Protein A/G MagBeads, GenScript). Bound proteins
were eluted with 0.1 M glycine, pH 2.3, then neutralized, resolved by SDS-PAGE,
and immunoblotted sequentially with mouse anti-ubiquitin (clone P4D1; sc-8017,
Santa Cruz Biotechnology) and rabbit anti-HIF-2α (ab109616, Abcam) antibodies.
For cycloheximide chase assays, 1G11-mock and -SOD3 cells were cultured in
hypoxia (3% O2, 37 °C, 6 h) and then treated with cycloheximide (50 μg/ml, 10
min; Sigma Aldrich) in hypoxia. Cells were then shifted to normoxia (21% O2) and
lysed at the indicated times using RIPA buffer supplemented with 1% SDS and a
complete Mini Protease Inhibitor Cocktail (Roche). Resolved proteins were
immunoblotted with anti-HIF-1α, -HIF-2α, and -tubulin antibodies; the HIF-1/2α/
tubulin ratio was calculated and expressed as a percentage relative to time 0.
Densitometric measurements for all immunoblots were performed with the
ImageJ software (NIH). Full immunoblots for main and supplementary figures are
shown in Supplementary Figs. 13 and 14, respectively
Immunohistochemistry. All methods for IHC and IF of mouse tumors have been
described33,62. Briefly, tumors were excised at days 16–18 after tumor cell inocu-
lation and snap-frozen in Tissue Freezing Medium (OCT; Jung) or fixed with 10%
neutral buffered formalin (3 h) and paraffin embedded. Sections (5–20 μm) were
prepared and used directly (frozen tissue) or deparaffinized, rehydrated, and
subjected to heat-induced epitope retrieval in citrate buffer (0.01 M sodium citrate
pH 6; 20 min). For immunostaining, the following rabbit antibodies were used:
anti-CD31 (MEC13.3, BD Bioscience), -SOD3 (Cloud Clone), -VEC (LS-B2138,
LSBio), -HIF-2α (PAI-32216, Thermo Fisher Scientific), and -3-NT (#06–284, Cell
Signaling). Sections were incubated with appropriate fluorescently conjugated
secondary antibodies (Alexa 488 or 546, Molecular Probes) or with peroxidase-
labeled anti-rabbit IgG (Dako), followed by amino ethyl carbazol (AEC; Enzo) and
hematoxylin counterstaining. Sections were mounted with 4,6-diamidino-2-phe-
nylindole (DAPI)-containing Fluoromount-G (SouthernBiotech; fluorescence
analyses) or Dako Faramount Aqueous Mounting Media (Dako; conventional
IHC) and analyzed with an Olympus FluoView 1000 confocal microscope with a
×60 1.4 oil plan-Apo objective or with a Leica (DM RB) microscope equipped with
an Olympus DP70 camera.
TMA analyses. Microarrays were prepared from hCRC samples43 and IHC was
performed in deparaffinized samples after antigen retrieval in citrate buffer (pH
6.0, 20 min) by incubation with goat anti-SOD3 (AF3420, R&D Systems), rabbit
anti-HIF-2α (NB100-122, Novus Biologicals), or mouse anti-CD34 antibodies
(QBEnd-10, M7165 Dako), followed by appropriate peroxidase-labeled secondary
antibodies. The reaction was developed with AEC or diaminobenzidine (CD34) as
chromogens, and hematoxylin counterstained. In all cases, sections from normal
colon mucosa distant from the tumor site were used as controls. Staining was
evaluated in a Leica DM500 optical microscope by a single pathologist (M.J.F.-A.)
blinded to experimental data. The percentage of stained cells and staining intensity
(scored as 1–3) were recorded for each gene, and the H-score was calculated as the
product of these parameters63 for the epithelial tumor cell compartment and for
tumor-associated stromal cells. In IF analyses, samples were incubated with all
three antibodies, followed by appropriate secondary antibodies. Images were cap-
tured on an Olympus FluoView 1000 confocal microscope.
HIF-1/2α staining and nuclear quantification. Immunofluorescence analyses of
cultured EC were performed in 1% gelatin-coated Nunc Lab-TEK chamber slides.
Untreated or L-NMMA (100 μM; Cayman)-treated cells were fixed with 4% par-
aformaldehyde (PFA; 10 min, 20 °C) for HIF-1α staining or with ethanol:acetic acid
(95:5, 1 min, −20 °C) for HIF-2α staining. Cells were then permeabilized with
0.1–0.3% Triton X-100 (5 min, 20 °C) and stained with rabbit anti-HIF-1α (PA1-
16601) or -HIF-2α (PAI-32216; Thermo for 1G11 cells; NB100-122; Novus Bio-
logicals for HDMEC cells), followed by Cy3-labeled goat anti-rabbit antibody;
nuclei were counterstained with DAPI Fluoromount-G (Southern Biotech). As
positive control for HIF-1α, 1G11 cells were treated with CoCl2 (100 μM, 6 h,
37 °C) before fixing. Images were acquired with a Leica DMI6000B microscope
equipped with a Hamamatsu camera ORCA-R2 (HIF-2α). An open source
MATLAB-based computational platform was developed for automatic quantifica-
tion of HIF-2α-associated fluorescence after background subtraction. Nuclei were
segmented using DAPI images and the segmentation applied to the Alexa546
channel to measure HIF-2α-stained pixels within the nuclear area; the ratio of
nuclear staining to total nuclear area was then calculated. Reactive oxygen species
levels in 1G11-mock and 1G11-SOD3 cells, alone or in tumor cell-conditioned
medium, were determined by staining of the dihydroethidium probe (2 μM, 30
min, 37 °C; Invitrogen).
Tumor perfusion. Tumor-bearing mice (days 18–21 post-LLC inoculation)
received injections (intravenous (i.v.)) of FITC-lectin (100 μg; Vector Laboratories)
and were heart-perfused with 10% neutral buffered formalin. Tumors were excised,
snap-frozen in OCT, and 50 μm-thick sections were analyzed with a Radiance 2100
confocal system (BioRad) on a Axiovent 200 microscope (Zeiss; excitation/detec-
tion 488/500–560 nm). In some experiments, vessels were 3D-reconstructed from
section stacks (1 μm step size) with Imaris v7.3.1 software (Bitplane). The number
of double (CD31 and lectin)- and single (CD31)-stained structures was determined
in tumor sections using ImageJ software. RGB images were transformed to 16–bit
and, after threshold adjustment, the Analyze Particle tool was applied using settings
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for particle size (>10 microns) and circularity (0–1). Perfusion was calculated as
the percentage of double-positive (CD31+lectin+) to CD31+ structures.
CD31 staining and quantification of blood vessel parameters. End-point
tumors were snap-frozen in OCT and 20 μm sections were stained sequentially
with anti-CD31 and fluorescently-labeled secondary antibodies. The number of
CD31-stained structures and average size were determined with Image J as above.
To determine other vessel parameters, we used histogram equalization to increase
contrast and allow detection of small and lightly stained structures. A Hessian-
based Frangi filter was then applied to enhance vessel fibrillar structure64. A vessel
mask was obtained by applying Otsu thresholding; this mask was used to visualize
vessel skeleton using morphological thinning operations to calculate length and
branch points of each vessel. Euclidean distance transform from the vessel mask to
the edge of segmentation was also performed. Vessel diameter was calculated by the
values of the Euclidean distance transform lying on the skeleton (central values).
All calculations were performed using MATLAB Release 2017a (The MathWorks).
For Vhcl- and Lov-treated tumors, lectin-perfused images (see above) were used for
analyses.
SEM was performed as reported33.
VEC staining and quantification. Tumor-bearing mice (day 17–20 post-LLC
inoculation) were perfused with 2% PFA in PBS, fixed in PFA, and included in
OCT. Tumor sections were stained with anti-VEC and -CD31 antibodies, followed
by appropriate labeled secondary antibodies, and analyzed in an Olympus Fluo-
View 1000 confocal microscope with a x60 1.4 oil plan-Apo objective. Images were
transformed to 8-bit with ImageJ and, after threshold adjustment, the Image cal-
culator tool was used to select CD31- and VEC-stained coincident regions. The
ratio between VEC- and CD31-stained areas was calculated and expressed as a
percentage.
For quantification of VEC-stained length in tumor vessels, images were
segmented based on CD31 staining using the Otsu method; this allowed the
selection of blood vessels. Hysteresis thresholding was applied to VEC staining in
the CD31 area. Morphological thinning was run to measure the length of VEC-
stained structures using MATLAB.
For VEC staining in human and mouse EC, cells were plated on 1% gelatin-
coated Lab-TEK chamber slides (Nunc), fixed with 4% PFA (10 min, 20 °C),
permeabilized with 0.25-0.3% Triton X-100 (5 min, 20 °C) and stained with
appropriate antibodies for mouse or human VEC (see above). In some
experiments, 1G11-mock and -SOD3 cells were pretreated with VEGF165 (50 ng/
ml, 2 h; Peprotech 450–32) before staining. Images were acquired with the
Olympus FluoView 1000 system. Junctional length and gap index were quantified
as described39, with a minimum of 5 fields/condition.
Permeability assays. In vivo vessel leakage was analyzed in tumor-bearing mice
(day 17) by i.v. co-injection of Texas Red-conjugated dextran 70 kDa (250 μg;
Molecular Probes) and FITC-lectin (100 μg). After perfusion with 2% PFA in PBS,
tumors were fixed (2% PFA, 3 h) and snap-frozen in Optimal Cutting Temperature
(OCT). Tumor sections were analyzed by confocal microscopy (Olympus FV1000),
and images were quantified using the confocal software (FV10-ASW, Olympus).
Vessel leakage is the ratio between fluorescence intensity of extravasated dextran
and perfused vessel counts.
For in vitro permeability analyses, 2 × 105 1G11 or HDMEC (stable, transfected
with indicated plasmids, or infected with Ad-hSOD3 or control) were seeded on
1% gelatin-coated transwells (24 mm diameter; 0.4 μm pore; Costar); this cell
concentration formed confluent monolayers after 24 h culture. Cell monolayers
were incubated with tumor cell-conditioned medium, and EC permeability was
assayed using FITC-dextran (40 kDa; 1 mg/ml) in phenol red-free DMEM. When
indicated, the pan-NOS inhibitor L-NMMA, different doses of the NO donor
DETA-NONOate or VEGF165 were added to cells before assay. Permeability was
determined by fluorescent readout in the lower chamber (FilterMax F5 Multi-mode
Reader, Molecular Devices). Fluorescence values were extrapolated to a standard
curve constructed using known amounts of FITC-dextran.
NO detection. For NO detection in vivo, Vhcl- and Lov-treated tumor-bearing
mice (day 18) were co-injected with FITC-lectin and the NO-sensitive fluorescent
probe DAR-1 (320 μg in dimethyl sulfoxide (DMSO); Sigma-Aldrich). After 1 h,
mice were perfused by intracardiac injection of PBS, and tumors were excised, fixed
with 2% PFA (3 h), and snap-frozen in OCT. Thick sections (40 μm) were analyzed
by confocal microscopy (Leica TSC SP5) and quantified with ImageJ; pseudocolor
images were obtained with the Leica confocal software (LAS AF 2.6.0).
Quantification of intracellular NO in EC was as described65. Briefly, 1G11 cells
were transduced with Ad-C and Ad-mSOD3 viruses and were incubated the next
day (3 h, 37 °C) with the NO-sensitive probe 4,5-diamofluorescein (DAF2, 10 μM;
Sigma-Aldrich). Cells were analyzed by FACS, using DAF2-untreated cells as
negative control.
Promoter assays. pGL3-VEC-Luc (2.4 kb VEC promoter)66 and p9xHIF-Luc67
plasmids were provided by Q. Xu (King’s College London British Heart Foundation
Centre) and L. del Peso (Universidad Autónoma de Madrid), respectively. Serial 5′-
deletion mutants of the VEC promoter were generated by PCR using pGL3-VEC-
Luc as template. HRE sites in the VEC promoter were mutated by replacing the
CGT sequence in the HRE consensus site68 with AAA or TTT, using the following
oligonucleotides for site-directed mutagenesis (HRE1: 5′GCTGAAAGTGATT
GTCTGTCTTTTTTCTCAGCTGCCCG3′; HRE2: 5′CCCTGGTTGGTCCATGGT
CAAAAGAAGCCCATCACCCAG3′, and HRE3: 5′GGATTAAAGGAAAGCGC
CACCTTTCCTGGCTGAATG3′).
For the reporter assays, 1G11 or 3T3 fibroblast cells were transiently transfected
using Lipofectamine 3000 (Thermo Fisher Scientific) with a mixture of plasmids
(500 ng total DNA) containing pGL3-VEC-Luc, pGL3-VEC-Luc mutants or
p9xHIF-Luc plus pRVIRES-gfp (mock control), pRVSOD3-IRES-gfp, pcDNA3-
hHIF1α, or pCMVSPORT6-HIF-2α, and pRL-SV40-Luc Renilla as internal control,
at a 6:3:1 ratio (for 1G11) or 4:8:1 (for 3T3). In experiments involving different
HIF-1α and HIF-2α doses, the transfected DNA amount was kept constant with an
empty pcDNA3 plasmid. In some experiments, transfected cells were incubated
with DETA-NONOate, L-NMMA, or IOX2 (Cayman), using an equivalent DMSO
concentration as vehicle. Firefly and Renilla luciferase activities were measured 72 h
posttransfection using the Dual-Luciferase Reporter Assay System (Promega).
Relative promoter activity was defined as the ratio of firefly activity to Renilla
activity, with that of control set as 1.0.
ChIP assay. ChIP assay was performed with the EZ-ChIP Kit (Millipore)
according to the protocol provided. Briefly, 1G11-mock and 1G11-SOD3 cells were
fixed (10 min, room temperature (RT)) with 1% PFA in culture medium and
quenched with glycine (5 min, RT). After medium removal, 2 × 107 cells/ml were
harvested in lysis buffer (4 °C, 15 min), and chromatin was sheared by sonication
(20 cycles of 30 s on and 30 s off; Bioruptor Pico, Diagenode) in aliquots of 0.2 ml.
As input reference, 1% of each cell lysate was stored; the remainder was immu-
noprecipitated (4 °C, 14 h with rotation) with rabbit anti-HIF-2α (NB100-122; 20
μg) or goat anti-KLF-4 antibody (sc12538, Santa Cruz Biotechnology; 10 μg) and
purified rabbit or goat IgG as respective controls. Immune complexes were cap-
tured using Protein G agarose beads, pelleted by centrifugation, and washed with
low-salt buffer, followed by high-salt buffer and Tris-EDTA buffer (25 mM Tris-
HCl, 150 mM NaCl, 1 mM EDTA, pH 7.2) to minimize nonspecific binding.
Chromatin immunocomplexes were eluted from beads with elution buffer (100
mM NaHCO3, 1% SDS), and the protein/DNA link was reversed by incubation (4
h, 65 °C) with 5 M NaCl, followed by proteinase K (10 μg/μl, 2 h, 45 °C). DNA was
then purified using spin columns, and VEC gene promoter sequences were ana-
lyzed by RT-qPCR with the primers ChIP1-(fw)5′GAAGTGCTACCCTGGCA-
GACGTG3′, (rev) 5′TCCATAGCATTCAACTACTGCGTG3′ (amplicon: 236 bp),
and ChIP2-(fw) 5′TTTGCTGACTCAGACCTATGGCTA3′, (rev)5′GGGCAGCT-
GAGAAACGTGACAGAC3′ (amplicon: 225 bp). Dissociation curves showed that
PCR yielded single products.
The relative quantity of amplified product in the input and ChIP samples was
determined as described69. Briefly, serial dilutions of the pGL3-VEC-Luc were
amplified and a standard curve was drawn in log2 base, plotting CT values (x axis)
vs. the corresponding dilutions (y axis). The CT values determined in ChIP and
input samples were calculated using this curve, and the value obtained was used to
calculate the power of two. The signal relative to input was calculated as the
fraction of ChIP to the input, after subtraction of the value obtained from IgG
ChIP. Data shown are ChIP results obtained from at least four independent
replicates.
Hydroxylase activity assay. Endogenous PHD activity was measured in mock-
and SOD3-transfected cells using HIF-1α as substrate70. Briefly, cells were tran-
siently transfected with pRVSOD3-IRES-gfp or pRVIRES-gfp using the calcium
phosphate method; transfection efficiency was 70–90%, as analyzed by FACS using
GFP as marker. Cell extracts were prepared at 48 h posttransfection using a
hypotonic buffer (20 mM Tris-HCl pH 7.5, 5 mM KCl, 1.5 mM MgCl2), mechan-
ical disruption with a Dounce homogenizer, and passage through a 30-g needle.
Soluble material was obtained by centrifugation (12,000 × g, 30 min, 4 °C). The
PHD activity of these extracts was analyzed by ELISA.
High-binding white 96-well plates were coated (overnight, 4 °C) with
ExtrAvidin (5 μg/ml; 100 μl/well; Sigma-Aldrich) in coating buffer (0.1 M
carbonate buffer pH 9.4). All other incubations were carried out at RT. After
blocking with 2% bovine serum albumin in PBS–0.1% Tween 20 (2 h), plates were
incubated (1 h) with 200 ng/well biotinylated HIF-1α peptide
(DLDLEMLAPYIPMDDDFQL; CNB Proteomics Service, Madrid, Spain); a
hydroxylated version of the peptide (DLDLEMLAP(OH)YIPMDDDFQL) was used
for specificity control assays. After three washing steps with PBS–0.1% Tween20
and one with hypotonic buffer, 200 μg/well of the cell extracts were used in a
hydroxylation reaction in hypotonic buffer (with 0.5 mM α-ketoglutaric acid, 0.1
mM FeCl2, and 0.5 M Na-L-ascorbate) (2 h). After five washing steps, 5 μl/well in
vitro-transcribed and translated HA-VHL protein (HA-VHL-pRc/CMVm
Addgene, plasmid 19,999) was added (2 h), followed by incubation (1 h) with a
peroxidase-conjugated mouse anti-HA antibody (clone HA-7; Sigma-Aldrich).
Peroxidase activity bound to the solid phase was detected with the Super-Signal
ELISA Pico chemiluminescent substrate (50 μl/well; Thermo Fisher Scientific), and
light emission was measured (200 ms) in an Infinite M200 microplate reader
(Tecan). Relative luminescence units are mean± SEM of triplicate samples.
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Statistical analysis. For in vitro experiments, data are shown as mean ± SEM of at
least three independent experiments with at least three technical replicates. For
in vivo experiments, data are shown as mean ± SEM of individual mice pooled
from at least two independent experiments. Sample size in animal studies was
estimated using the power method, and values corrected for 20% attrition. For
staining of in vivo material, at least five mice were used. For data with normal
distribution and homogeneity of variances, statistical significance was calculated
with a two-tailed Student’s t-test for comparison of two independent groups and
one-way or two-way ANOVA with Dunnett’s, Tukey’s, or Bonferroni’s post-hoc
test for multiple comparisons. When the above requirements were not fulfilled,
data were analyzed using non-parametric tests. Correlation analyses were per-
formed using the non-parametric Spearman’s rank correlation coefficient. Differ-
ences were considered significant when p < 0.05. All statistical analyses were
performed using the Prism software.
Data availability. The authors confirm that all relevant data and materials sup-
porting the findings of this study are available on reasonable request. This excludes
materials obtained from other researchers, who must provide their consent for
transfer.
Code availability. MATLAB programs generated for HIF-2α image quantification
can be accessed on reasonable request.
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